Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2005

View Archived Issues

Infliximab shows promise in the treatment of refractory PUK

Memory Pharmaceuticals and Amgen sign agreement on PDE10 inhibitors

Norwood Immunology signs agreement for phase II melanoma vaccine trial

Companies advance various approaches to avian flu

Organizations report discovery of agents for heart failure, arrhythmia, etc.

Repligen in expanded uridine agreement for bipolar disorder

The Vaccine Company secures funding for phase III AML study of PR1 vaccine

Novel treatment options for hepatic disorders described in recent patent literature

Syntonix and Boehringer Ingelheim to optimize therapeutic peptides for inhalation

Lilly to support study of Corlux to mitigate olanzapine-associated weight gain

Method to predict/detect age-related macular degeneration reported by the University of Iowa

Oxycyte produces positive results in preclinical traumatic brain injury study

Hyzaar 100-12.5 mg now available

BCY LifeSciences signs letter of intent for business combination with Pipex

Phase II study of Gabapentin GR completes enrollment

Recombinant osteoprotegerin shows potential in juvenile Paget's disease

New mGluR1 antagonist shows promise as an analgesic

Abbott profiles its new highly selective dopamine D4 receptor agonist

Blocking P-glycoprotein increases Abeta accumulation

Bevacizumab improves visual acuity of patients with neovascular AMD

Clinical evidence supports the use of Evizon in wet AMD

Trastuzumab significantly improves disease-free survival in early stage HER2-positive breast cancer

Lurasidone effective in acute exacerbation of schizophrenia

Cognitive parameters improved with ispronicline in age-associated memory impairment

CV Therapeutics withdraws ranolazine MAA with plans to resubmit

Japanese approval for Avelox

Tostrex launched in Sweden

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...